研究发现,Semaglutide是一种糖尿病药物,在扭转严重的肝病方面很有希望。 Semaglutide, a diabetes drug, shows promise in reversing severe liver diseases, study finds.

《新英格兰医学杂志》的一项新研究表明,用于2型糖尿病的药物Semaglutide也可以扭转严重的肝脏疾病,如代谢性机能失调相关的steatohepatitis(MASH)等。 A new study in The New England Journal of Medicine shows that semaglutide, a drug used for type 2 diabetes, can also reverse severe liver diseases like metabolic dysfunction associated steatohepatitis (MASH). 在试验中,接受塞马格卢提德治疗的参与者中,62. 9% 患者的肝炎和脂肪减少,而安慰剂组的患者数量为 34. 3%. In the trial, 62.9% of participants treated with semaglutide saw reduced liver inflammation and fat, compared to 34.3% in the placebo group. 该药物还导致体重下降约10.5%,有可能为肝病提供新的治疗办法。 The drug also led to about 10.5% weight loss, potentially offering a new treatment option for liver diseases.